Midway through the 2007 Congressional debate over new drug safety controls, Mark McClellan, MD, is emerging as a figure with the credentials, credibility and fund-raising capability to make the establishment of a public-private partnership for post-marketing surveillance a reality. Big Pharma better hope that McClellan is ultimately successful. If ever there was a time when a new, authoritative voice was needed to provide clarity to postmarketing safety issues, it is now.
Midway through the Congressional debate over new drug safety
controls, Mark McClellan, MD, is emerging as a figure with the
credentials, credibility and fund-raising capability to make the
establishment of a public-private partnership for post-marketing
surveillance a reality.
Big Pharma better hope that McClellan is ultimately successful. If ever there was a time when a new, authoritative voice...